PDL BioPharma, Inc. (NASDAQ:PDLI) Files An 8-K Other EventsItem 8.01 Other Events.
On May 21, 2018, the Company issued a press release announcing the appointment of Jill Jene, Ph.D., as vice president of business development, effective as of May 18, 2018. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
PDL BIOPHARMA, INC. ExhibitEX-99.1 2 pdli-201805188xkex991.htm PRESS RELEASE Exhibit Exhibit 99.1PDL BioPharma Names Dr. Jill Jene Vice President,…To view the full exhibit click here
About PDL BioPharma, Inc. (NASDAQ:PDLI)
PDL BioPharma, Inc., formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. The Company provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions and inventors. It evaluates its investments based on the quality of the income generating assets and potential returns on investment. It is focused on intellectual property asset management, acquiring income generating assets and maximizing value for its stockholders, among others. It receives royalties on sales of over ten humanized antibody products, which include Avastin, Herceptin, Xolair, Kadcyla, Tysabri, Actemra, Gazyva and Entyvio all of which are approved for use.
